Journal article
Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials
Abstract
Multiple immunotherapeutics have been approved for cancer patients, however advanced solid tumors are frequently refractory to treatment. We evaluated the safety and immunogenicity of a vaccination approach with multimodal oncolytic potential in non-human primates (NHP) (Macaca fascicularis). Primates received a replication-deficient adenoviral prime, boosted by the oncolytic Maraba MG1 rhabdovirus. Both vectors expressed the human MAGE-A3. No …
Authors
Pol JG; Acuna SA; Yadollahi B; Tang N; Stephenson KB; Atherton MJ; Hanwell D; El-Warrak A; Goldstein A; Moloo B
Journal
OncoImmunology, Vol. 8, No. 1,
Publisher
Taylor & Francis
Publication Date
January 2, 2019
DOI
10.1080/2162402x.2018.1512329
ISSN
2162-4011